Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 424-434

  Rybalkin, Sergei D ^a   Bornfeldt, Karin E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLINE; ENOXIMONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE; ROLIPRAM;

ARTERY MUSCLE; BLOOD VESSEL INJURY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; PRIORITY JOURNAL; SPECIES DIFFERENCE; TISSUE SPECIFICITY;

EID: 0032698044     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615862     Document Type: Conference Paper

References (91)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Loesberg C, van Wijk R, Zandbergen J, van Aken WG, van Mourik JA, de Grooth PG Cell cycle-dependent inhibition of human vascular smooth muscle cell proliferation by prostaglandin E1. Exp Cell Res. 1985:160:117-125.
3. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth muscle cells. Biochem J. 1992;288:527-532.
4. Bornfeldt KE, Krebs EG. Crosstalk between protein kinase A and growth factor receptor signaling pathways in arterial smooth muscle. Cell Signal. In Press.
5. Sarkar R, Gordon, Stanley JC, Webb RC. Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. J Hypertens. 1997;15:275-283.
6. Sarkar R, Webb RC. Does nitric oxide regulate smooth muscle cell proliferation? J Vasc Res. 1998;35:135-142.
7. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365-375.
8. Raines EW, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 1993;69:S30-S37.
9. Reidy MA. Neointimal proliferation: the role of basic FGF on vascular smooth muscle cell proliferation. Thromb Haemost. 1993;70:172-176.
10. Rabinovitch M. Investigational approaches to pulmonary hypertension. Toxicol Pathol. 1991;19:458-469.
11. Gordon D, Rekhter MD. The growth of human atherosclerosis: cell proliferation and collagen synthesis. Cardiovasc Pathol. 1997;6:103-116.
12. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest. 1995;96:141-149.
13. Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, Yatomi Y, Sidhu JS, Krebs EG, Hakomori S, Ross R. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol. 1995;130:193-206.
14. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996:78;225-230.
15. Palmer D, Tsoi K, Maurice DH. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res. 1998;82:852-861.
16. Kaji T, Inada M, Yamamoto C, Fujiwara Y, Koizumi F. Cyclic AMP-dependent pathway that mediates suppressive regulation of glycosaminoglycan production in cultured vascular endothelial cells. Thromb Res. 1996;82:389-397.
17. Passaretti TV, Wilcox BD, Jeffrey JJ. Serotonin regulation of gene expression in uterine extracellular matrix: reciprocal effects on collagens and collagenase. Mol Cell Endocrinol. 1996;120:125-132.
18. Dey NB, Boerth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM. Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res. 1998;82:139-146.
19. Boerth NJ, Dey NB, Cornwell TL, Lincoln TM. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J Vasc Res. 1997;34:245-259.
20. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G, Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nature Med. 1997;3:775-779.
21. Furuya M, Miyazaki T, Honbou N, Kawashima K, Ohno T, Tanaka S, Kangawa K, Matsuo-H. C-type natriuretic peptide inhibits intimai thickening after vascular injury. Ann NY Acad Sci. 1995;748:517-523.
22. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C, Zoldhelyi P, Gerard R, Collen D. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97:1274-1281.
23. Schror K, Weber AA. Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions. 1997;Suppl. 48:63-91.
24. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A.
25. Lablanche J-M, Grollier G, Lusson J-R, Bassand J-P, Drobinski G, Bertrand B, Battaglia S, Desveaux B, Juillière Y, Juliard J-M, Metzger J-P, Coste P, Quiret J-C, Dubois-Randé J-L, Crochet PD, Letac B, Boschat J, Virot P, Finet G, Le Breton H, Livarek B, Leclercq F, Béard T, Giraud T, McFadden EP, Bertrand ME. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Circulation. 1997;95:83-89.
26. Walsh DA, Van Patten SM. Multiple pathway signal transduction by the cAMP-dependent protein kinase. FASEB J. 1994;8:1227-1236.
27. Dell'Acqua ML, Scott JD. Protein kinase A anchoring. J Biol Chem. 1997;272:12881-12884.
28. Murad F. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA. 1996;276:1189-1192.
29. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 1994;267:C1405-1413.
30. Vaandrager AB, de Jonge HR. Signalling by cGMP-dependent protein kinases. Mol Cell Biochem. 1996;157:23-30.
31. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther. 1991;50:123-145.
32. Wang X, Robinson PJ. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem. 1997;68:443-456.
33. Vo NK, Gettemy JM, Coghlan VM. Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs). Biochem Biophys Res Commun. 1998;246:831-835.
34. Boynton AL, Whitfield JF. The role of cyclic AMP in cell proliferation: a critical assessment of the evidence. Adv Cycl Nucl Res. 1983;15:193-294.
35. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation. 1997;95:1269-1277.
36. Bornfeldt KE. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc Med. 1996;6:143-151.
37. Seger R, Krebs. The MAPK signaling cascade. FASEB J. 1995;9:726-735.
38. Servant MJ, Giasson E, Meloche S. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J Biol Chem. 1996;271;16047-16052.
39. Bornfeldt KE, Campbell JS, Koyama H, Argast GM, Leslie CC, Raines EW, Krebs EG, Ross R. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets. J Clin Invest. 1997;100:875-885.
40. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC. Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg. 1998;27:117-125.
41. Graves LM, Bornfeldt KE, Raines EW. Potts BC, Macdonald SG, Ross R, Krebs EG. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA. 1993;90:10300-10304.
42. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
43. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng Q-P, Kasuga M, Nishimoto I, Avruch J. Regulation of eIF-4E phosphorylation by mTOR. J Biol Chem. 1997;272:26457-26463.
44. Lawrence JC Jr, Fadden P, Haystead TAJ, Lin T-A. PHAS proteins as mediators of the actions of insulin, growth factors and cAMP on protein synthesis and cell proliferation. Adv Enzyme Regul. 1997;37:239-267.
45. Scott PH, Lawrence JC. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J Biol Chem. 1998;273:34496-34501.
46. Scott PH, Belham CM, al Hafidh J, Chilvers ER, Peacock AJ, Gould GW, Plevin R. A regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells. Biochem J. 1996;318:965-971.
47. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA. 1998;96:7772-7777.
48. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997;16:3693-3704.
49. Meyuhas O, Avni D, Shama S. Translational control of ribosomal protein mRNAs in eukaryotes. Translational Control. 1996;30:363-388.
50. Proud CG. p70 S6 kinase: an enigma with variations. Trends Biochem Sci. 1996;21:181-185.
51. Kumar R, Cartledge WA, Lincoln TM, Pandey KN. Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells. Role of cGMP and cGMP-dependent protein kinase. Hypertension. 1997;29:414-421.
52. Dhaunsi GS, Matthews C, Kaur K, Hassid A. NO increases protein tyrosine phosphatase activity in smooth muscle cells: relationship to antimitogenesis. Am J Physiol. 1997;272:H1342-1349.
53. Awazu M. Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide. Kidney Int. 1997;52:356-362.
54. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994:79:551-555.
55. Vadiveloo PK, Filonzi EL, Stanton HR, Hamilton JA. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis. 1997;133:61-69.
56. Kato JY, Matsuoka M, Polyak K, Massagué J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kipl) of cyclin-dependent kinase 4 activation. Cell. 1994;79:487-496.
57. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
58. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21 (Sdi1/Cip1/Waf1) by nitric oxide-generation vasodilator in vascular smooth muscle cells. J Biol Chem. 1997;272:10050-10057.
59. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
60. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA. 1998;95:8991-8996.
61. Soderling SH, Bayuga SJ, Beavo JA. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. JBiol Chem. 1998b;273:15553-15558.
62. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 1998;246:570-577.
63. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human-specific phosphodiesterase. J BM Chem. 1998;273:15559-15564.
64. Lougnney K, Martin TJ, Harris EAS, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA, Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J BM Chem. 1996;271:796-806.
65. Van C, Zhao AZ, Bentley JK, Lougnney K, Ferguson K, Beavo JA. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci USA.. 1995;92:9677-9681.
66. Yan C, Zhao AZ, Bentley JK, Beavo JA. The calmodulin-dependent phosphodiesterase gene PDElC encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem. 1996;271:25699-25706.
67. Manganiello VC, Taira M, Degerman E, Beifrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell Signal. 1995;7:445-455.
68. Nagaoka T, Shirakawa T, Kasuya J, Balon TW, Manganiello VC, Fujita-Yamaguchi Y. Cyclic nucleotide PDE-3. Quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay. Cell Biochem Biophys. 1998;29:49-66.
69. Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 1995;16:370-389.
70. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, Omori K. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem. 1998;255:391-399.
71. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson-K. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene. 1998;216:139-147.
72. Hurwitz RL, Hirsch KM, Clark DJ, Holcombe VN, Hurwitz MY. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J Biol Chem. 1990;265:8901-8907.
73. Jiang X, Jianping L, Paskind M, Epstein PM. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA. 1996;93:11236-11241.
74. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997;100:2611-2621.
75. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD. ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol. 1998;274:H448-H455.
76. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res. 1998;43:163-168.
77. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med. 1998;158:279-288.
78. Ivorra MD, Le Bee A, Lugnier C. Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle. J Cardiavasc Pharmacol. 1992;19:532-540.
79. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isoenzymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-L543.
80. Ross R, Kariya B. Circulation, Vascular smooth muscle. In: Bohr DF, Somlyo AP, Sparks V, eds. Handbook of Physiology - The cardiovascular system. Bethesda: American Physiological Society 1980;69-91.
81. Sonnenburg WK, Rybalkin SD, Bomfeldt KE, Kwak KS, Rybalkina IG, Beavo JA. Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods. 1998;14:3-19.
82. Xiong Y, Westhead EW, Slakey LL. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem J. 1995;305:627-633.
83. Maurice DH. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP. Cell Biochem Biophys. 1998;29:35-47.
84. Souness JE, Hassall GA, Parrott DP. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 1992;44:857-866.
85. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 1994;48:827-835.
86. Johnson-Mills K, Arauz E, Coffey RG, Krzanowski JJ Jr, Polson JB. Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl)phenyl]-5-methyl- monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. Biochem Pharmacol. 1998;56:1065-1073.
87. Lindgren S, Rasc'on A, Andersson KE, Manganiello V, Degerman E. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem Pharmacol. 1991;42:545-552.
88. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J. 1995;8:637-642.
89. Ciapa B, Pesando D, Wilding M, Whitaker M. Cell-cycle calcium transients driven by cyclic changes in inositol trisphosphate levels. Nature. 1994;368:875-878.
90. Hepler PK. Calcium and mitosis. Int Rev Cytol. 1992;138:239-268.
91. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: recent advances. FASEB J. 1996;10:283-292.